Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment offers bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. Its Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services in the areas of clinical chemistry, immunoassay, hematology, and microbiology for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District Of Columbia.

Danaher Corporation

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sarepta Therapeutics (SRPT – Research Report), Dan...

Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT), Danaher (DHR) and BridgeBio Pharma (BBIO)

UBS analyst maintained a Buy rating on Danaher today and set a price target of $270.00. In addition to UBS, Danaher also received a Buy from Barcla...

UBS Reaffirms Their Buy Rating on Danaher (DHR)

In a report released yesterday, Subbu Nambi from Guggenheim reiterated a Buy rating on Danaher, with a price target of $275.00. The company’s share...

Guggenheim Sticks to Its Buy Rating for Danaher (DHR)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Danaher (DHR – Research Report), Nurix Therapeutics ...

Analysts Are Bullish on These Healthcare Stocks: Danaher (DHR), Nurix Therapeutics (NRIX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on HCA Healthcare (HCA – Research Report) and Danaher (...

Analysts Offer Insights on Healthcare Companies: HCA Healthcare (HCA) and Danaher (DHR)

Here’s a look at today’s most important earnings reports from major publicly traded companies. Investors will be paying close attention to the resu...

These Are the Stocks Reporting Earnings Today – January 28, 2026

U.S. stocks finished the week mixed as gains in technology shares helped offset weakness in financial stocks and rising rate pressure. The Dow Jone...

The Week That Was, The Week Ahead: Macro and Markets, Jan. 25

Dhruv Consultancy Services Ltd. ( ($IN:DHRUV) ) has issued an update. Dhruv Consultancy Services Limited has submitted to BSE and NSE a compliance ...

Dhruv Consultancy Files SEBI Dematerialisation Compliance Certificate for Q3 FY2025-26

Kepler Capital analyst Baptiste de Leudeville maintained a Hold rating on Agrana Beteiligungs on January 14 and set a price target of €12.30. The c...

Kepler Capital  Remains a Hold on Agrana Beteiligungs (0DHR)

Kepler Capital analyst Baptiste de Leudeville maintained a Hold rating on Agrana Beteiligungs on January 8 and set a price target of €12.30. The co...

Agrana Beteiligungs (0DHR) Gets a Hold from Kepler Capital

Citi analyst Patrick B Donnelly maintained a Buy rating on Danaher on January 2. The company’s shares closed last Friday at $230.40. B Donnelly cov...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	DHR	$217.71	-2.56%	2.03M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	DHR	$217.71	-2.6%	2.03M
3
4
5
6

DHR

DHR

No Data Available

Get Danaher Corporation Data in Excel

Get Danaher Corporation Data in Excel